Evidence map›Paper›PMID 35243459›Full record

ArticleThe Lancet regional health. Western Pacific2022

Rates of intravenous thrombolysis and endovascular therapy for acute ischaemic stroke in China between 2019 and 2020.

Qing Ye, Feifei Zhai, Baohua Chao, Lei Cao, Yun Xu, Peilan Zhang, Hongxing Han, Lihua Wang, Bing Xu, Wenhuo Chen and 8 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Lancet regional health. Western Pacific, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06848894 (Efficacy and Safety of Human Urinary Kallidinogenase for Acute Ischemic Stroke Patients Receiving Reperfusion Treatment), which is not on this map. Cited by 53 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06848894 narecruitingnot on this mapstarted 2025, after this paper: background citation

Efficacy and Safety of Human Urinary Kallidinogenase for Acute Ischemic Stroke Patients Receiving Reperfusion Treatment

TypeinterventionalSponsorBeijing Tiantan HospitalRan2025 to 2027Enrolled1,204ConditionsAcute Ischemic StrokeArmsHuman urinary kallidinogenase (HUK), Placebo
3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Safety and tolerability of Rinvecalinase Alfa (DM199) for acute ischemic stroke (ReMEDy1).International journal of stroke : official journal of the International Stroke Society · 2026
    Trial
  6. Trial
  7. Trial
  8. Mean arterial pressure and pulse pressure trajectories and clinical outcomes after acute ischemic stroke.Hypertension research : official journal of the Japanese Society of Hypertension · 2026
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Qing YeDepartment of Neurology, Drum Tower Hospital, Medical School of Nanjing University, Nanjing, China.
Feifei ZhaiDepartment of Neurology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Science, Beijing, China.
Baohua ChaoThe General Office of Stroke Prevention Project Committee, National Health Commission of the People's Republic of China, Beijing, China.
Lei CaoThe General Office of Stroke Prevention Project Committee, National Health Commission of the People's Republic of China, Beijing, China.
Yun XuDepartment of Neurology, Drum Tower Hospital, Medical School of Nanjing University, Nanjing, China.
Peilan ZhangDepartment of Neurology, Tianjin Huanhu Hospital, Tianjin, China.
Hongxing HanDepartment of Neurology, Linyi People's Hospital, Shandong, China.
Lihua WangDepartment of Neurology, The Second Affiliated Hospital, Harbin Medical University, Harbin, China.
Bing XuDepartment of Neurology and Neuroscience, Shenyang First People's Hospital, Liaoning, China.
Wenhuo ChenDepartment of Neurointervention, Zhangzhou affiliated Hospital of Fujian Medical University, Fujian, China.
Changming WenDepartment of Neurology, Nanyang Central Hospital, Nanyang, China.
Shouchun WangDepartment of Neurology, The First Hospital of Jilin University, Jilin, China.
Runqing WangDepartment of Neurology, Zhengzhou Central Hospital, Zhengzhou, China.
Liyong ZhangDepartment of Neurosurgery, Liaocheng People's Hospital, Shandong, China.
Liqun JiaoDepartment of Neurosurgery, Xuanwu Hospital, Capital Medical University, Beijing, China.
Sheng LiuDepartment of Interventional Radiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Yi-Cheng ZhuDepartment of Neurology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Science, Beijing, China.
Long-De WangThe General Office of Stroke Prevention Project Committee, National Health Commission of the People's Republic of China, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn recent years, a series of initiatives have been launched to promote intravenous thrombolysis (IVT) and endovascular therapy (EVT) for acute ischaemic stroke (AIS) in China. We aimed to update the rates of IVT and EVT in China between 2019 and 2020 and to evaluate the current IVT and EVT according to hospital grades.

methodsCross-sectional data on patients receiving IVT/EVT were derived from the Bigdata Observatory platform for Stroke of China (BOSC). The monthly number of discharged patients with a principal diagnosis of AIS was derived from the first pages of medical records of each hospital. The rates and information of IVT and EVT were analysed according to hospital grades.

findingsDuring this period, 938 tertiary hospitals and 786 secondary hospitals from 31 provinces continuously reported data to the BOSC. The overall IVT rate for AIS was 5·64%, and the EVT rate was 1·45%. The IVT rate in secondary hospitals was higher than that in tertiary hospitals (6·39%

interpretationThe rates of IVT and EVT for AIS have greatly increased in China, but there is still a large gap compared with developed countries. Hospital inhomogeneity in IVT and EVT suggests the importance of developing a region-specific network for stroke treatment.

fundingNone.

Indexed as

Acute ischaemic strokeAIS, Acute ischaemic strokeBigdata Observatory platform for Stroke of ChinaBOSC, Bigdata Observatory platform for Stroke of ChinaEndovascular therapy rateEVT, Endovascular therapyIntravenous thrombolysis rateIVT, Intravenous thrombolysisSecondary hospitalsTertiary hospitals

Identifiers

PMID35243459
PMCPMC8873940

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.